The Zacks Analyst Blog Highlights Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch
For Immediate Release
Chicago, IL – January 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Nike, Inc. NKE, Novartis AG NVS, Wells Fargo & Co. WFC, Broadcom Inc. AVGO and Anheuser-Busch InBev SA/NV BUD.
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Nike, Novartis and Wells Fargo
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike, Inc., Novartis AG and Wells Fargo & Co.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Nike have held up a lot better in last year's tough market; down -13.4% vs. down -26% for the Zacks Consumer Discretionary sector and the S&P 500 index's -15.7% decline. A steadily growing direct-to-consumer (DTC) business and the China reopening are some of the key positives in the Nike story.
These big-picture positives notwithstanding, the Zacks analyst flagged margin pressures due to higher costs and bigger markdowns. The company provided a bleak view for fiscal 2023 and second-quarter driven by expectations of higher markdowns during the holiday season and slowed demand for NIKE's brands, including Jordan and Converse, due to reduced discretionary spending.
The Zacks analyst believes that the gross margin headwinds and the weakness in Greater China to continue hurting NIKE results in the quarters ahead.
However, NKE's robust surprise trend continued in the fiscal first quarter with earnings and sales surpassing estimates for the ninth and fourth straight quarter, respectively.
(You can read the full research report on NIKE here >>>)
Shares of Novartis have gained +0.6% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +14.6%. The company has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio, and the launch of Kesimpta continue to boost performance.
The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also boost performance further. The pipeline progress is also impressive and the company has some promising candidates. Management's focus on cost savings should boost the bottom line as well.
Management recently decided to spin off its generics business Sandoz into a separate company to focus on its core pharma business. However, generic competition for key drugs and pipeline setbacks also remains a concern.
(You can read the full research report on Novartis here >>>)
Shares of Wells Fargo have underperformed the Zacks Banks - Major Regional industry over the past year (-23.8% vs. -20.8%). The company is facing dismal non-interest income, higher provisions and weakness in the mortgage business which were the major undermining factors. Also, the rise in non-interest expenses acted as a headwind.
Wells Fargo is focused on maintaining its financial position despite several legal tensions. Also, it is likely to face challenges in improving revenues due to macroeconomic and geopolitical concerns.
Nevertheless, the company is working on its strategic initiatives, which will likely help regain the confidence of its clients and shareholders. Improving loan demand, rise in interest rates and manageable expense levels are encouraging.
(You can read the full research report on Wells Fargo here >>>)
Other noteworthy reports we are featuring today include Broadcom Inc. and Anheuser-Busch InBev SA/NV.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Wells Fargo & Company (WFC) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
NIKE, Inc. (NKE) : Free Stock Analysis Report
Broadcom Inc. (AVGO) : Free Stock Analysis Report
AnheuserBusch InBev SANV (BUD) : Free Stock Analysis Report
To read this article on Zacks.com click here.